BICO subsidiary Cytena has reached a $10 million agreement with Applitech Pharmaceutical Equipment Technology to distribute its single-cell isolators in China with the intent to develop novel treatments such as gene therapies, biosimilars and monoclonal antibodies.
The two-year deal encompasses the use of almost 100 of Cytena’s single-cell isolators, including the UP.SIGHT devices. China represents the world’s second-largest life science market.
“The life science market in China is one of the most impressive in the world, and we’re thrilled with this deal to be able to help researchers there accelerate their life-saving work,” said Erik Gatenholm, CEO and co-founder of BICO, in a press release.
In October, Cytena debuted the C.Station automated cell line development platform for antibody and gene therapies.
Deloitte estimated that China’s pharmaceutical market was worth $220 billion in 2020.
Filed Under: Drug Discovery, Drug Discovery and Development